Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?
Palabras clave : 
PD-1 inhibitor nivolumab
Cell lung cancer
Fecha de publicación : 
Editorial : 
AME Publishing
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Perez-Gracia, J.L. (Jose Luis); Fernandez-Sanmamed, M. (Miguel); Melero, I. (Ignacio). "Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?". Translational lung cancer research. 7 (Supl. 4), 2018, 356 - 357
Recently, Forde et al. reported in the New England Journal of Medicine a pilot study in which two neoadjuvant doses of the PD-1 inhibitor nivolumab were administered in a preoperative fashion to 21 patients with untreated, surgically resectable early (stage I–IIIA) non-small cell lung cancer (NSCLC) (1). Surgery was performed 4 weeks after the first dose of nivolumab. In addition to an acceptable toxicity profile, which did not cause delays in surgery, nivolumab induced a major pathological response in 9 of 20 resected tumors (45%). Pathological responses were observed in patients presenting PD-L1 positive and negative tumors and, interestingly, they correlated with pretreatment tumor mutational burden. The authors found that the number of T-cell clones observed in the tumor and peripheral blood increased following nivolumab in eight of nine patients. Remarkably, the authors described one patient presenting a complete response in which neoantigen-specific T-cell clones from the primary tumor rapidly expanded in peripheral blood following treatment. Moreover, some of these clones were not detected before treatment with nivolumab, thus suggesting that PD-1 blockade induced their expansion.

Ficheros en este ítem:
Vista previa
114.66 kB
Adobe PDF

Estadísticas e impacto

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.